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A B S T R A C T
While human immunodeﬁciency virus (HIV) infection has become a treatable disease with the development of
combination antiretroviral therapy (cART), chronic inﬂammation that aﬀects the central nervous system and
other organs is still common. Reliable methods are needed to study HIV-associated inﬂammatory biomarkers. In
this study involving both plasma and cerebrospinal ﬂuid (CSF), we compared multiplex bead array (MBA) to a
relatively new technology based on microﬂuidics and glass nanoreactor (GNR) technology for the measurement
of three commonly studied markers from HIV-infected individuals. We found that results correlated between the
two platforms for MCP-1 in both ﬂuids as well as for plasma TNFα (all p < .005). However, results between the
two platforms did not correlate for CSF TNFα or fractalkine from plasma or CSF. A statistically signiﬁcant
decrease in CSF TNFα over time (p < .0001) was only detectable with the MBA platform, and TNFα on the MBA
was the only CSF biomarker to correlate with CSF HIV RNA (rho= 0.71, p < .0001). Meanwhile, the GNR
platform was superior in terms of intra-assay fractalkine (FKN) variability and the detection of a signiﬁcant FKN
decrease over time. Additionally, the only signiﬁcant correlation between blood biomarkers and plasma HIV
RNA was with FKN on the GNR platform (rho=0.38, p= .015). Given the variability in results between
platforms, more research is needed on methods to quantitate HIV-associated inﬂammation.
1. Introduction
While combination antiretroviral therapy (cART) has transformed
HIV infection into a treatable disease, the infection is linked to an in-
crease in systemic inﬂammation despite optimal virologic suppression
during cART (Neuhaus et al., 2010). This persistent inﬂammatory state
is associated with multiple unfavorable clinical outcomes, including
increased mortality (Duprez et al., 2012). Numerous central nervous
system (CNS) ﬁndings during HIV have also been linked to inﬂamma-
tion. Speciﬁcally, HIV-associated neurocognitive disorder (HAND),
which continues to be highly prevalent in the cART era (Heaton et al.,
2010), appears to have inﬂammatory underpinnings (Burdo et al.,
2013; Saylor et al., 2016). Additionally, inﬂammation during HIV has
been associated with neuroimaging ﬁndings of decreased neuronal in-
tegrity, glial proliferation, and membrane turnover (Anderson et al.,
2015a; Anderson et al., 2015b). However, multiple diﬀerent in-
ﬂammatory pathways appear to be dysregulated during HIV (Deeks
et al., 2013), meaning that a more comprehensive understanding of
inﬂammation is needed to most eﬀectively address the long term eﬀects
of the infection. This includes more research on how HIV-associated
inﬂammation changes over time, which has become a surrogate out-
come in early phase studies of anti-inﬂammatory agents to treat in-
dividuals with chronic HIV (Probasco et al., 2008).
Methods that are highly automated yet sensitive may facilitate the
study of HIV-associated inﬂammatory markers by allowing for easier
scalability and the minimization of operator error. Currently available
methods include (but are not limited to) enzyme linked immunosorbent
assay (ELISA), chemiluminescence, and multiplex bead array (MBA).
One version of MBA relies on multiple diﬀerent colors of beads, with
each unique color bead being coupled to a single analyte-speciﬁc
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antibody (Luminex xMAP technology, Luminex corp, Austin, Texas).
Fluorescence levels are then quantitated after laser interrogation. A
newer method for the quantitation of inﬂammatory markers is based on
microﬂuidics and glass nanoreactor (GNR) technology (Simple Plex,
Protein Simple corp, San Jose, California). Brieﬂy, samples are loaded
into a cartridge with multiple microﬂuidic circuits, with each circuit
having lanes with a speciﬁc detection antibody for each analyte (Aldo
et al., 2016). Each lane has three GNR's through which the sample
travels, resulting in a triplicate reading for each sample. Within the
GNR, analytes are immobilized with capture antibodies and ﬂuores-
cence is then measured after administration of streptavidin-associated
dye. Speciﬁc standard curves are generated for each cartridge lot by the
company prior to shipment.
For the current study, we compared MBA and GNR platforms for the
quantitation of inﬂammatory markers from the paired plasma and
cerebrospinal ﬂuid (CSF) samples of HIV-infected participants before
and after initiation of cART. Three markers that have been associated
with HAND and are common between the two platforms were selected:
monocyte chemotactic protein 1 (MCP-1, also known as CCL-2), tumor
necrosis factor alpha (TNFα), and fractalkine (FKN, also known as
CX3CL1). MCP-1 is a chemokine that attracts/activates monocytes and
has been associated with both decreased neuropsychological perfor-
mance and markers of neuronal injury during HIV (Woods et al., 2006;
Anderson et al., 2015b). TNFα is a potent pro-inﬂammatory cytokine
that remains elevated in the blood throughout the course of HIV in-
fection (Wada et al., 2015). This cytokine has neurotoxic properties and
has also been associated with HAND (Sevigny et al., 2004). FKN is a
chemokine which attracts multiple immune cells, including microglia.
This chemokine is upregulated in the brain and CSF of individuals with
HIV-associated dementia (Cotter et al., 2002). In vivo models have
shown that FKN receptor deﬁciency dysregulates microglial responses,
resulting in neurotoxicity (Cardona et al., 2006). Therefore, it has been
postulated that FKN may have an important role in neuroprotection.
2. Materials and methods
2.1. Study participants
Participants were enrolled between 2013 and 2017 at the Emory
University Center for AIDS Research (CFAR) clinical core site in Atlanta
as part of ongoing studies on HIV and neurocognition, in which parti-
cipants oﬀ cART (either cART naïve or oﬀ cART for at least six months)
were enrolled and then had a second visit 24–48weeks after the in-
itiation of therapy. Individuals with chronic HIV between 18 and
59 years of age were eligible for participation. Individuals were ex-
cluded from the study for any of the following: 1) history of any neu-
rologic disease known to aﬀect memory (including stroke, malignancy
involving the brain, traumatic brain injury, and AIDS-related opportu-
nistic infection of the central nervous system); 2) current ongoing
substance use (marijuana use in the last 7 days OR cocaine, heroin,
methamphetamine, or other non-marijuana illicit drug use in the last
30 days); 3) heavy alcohol consumption in the last 30 days (deﬁned
as> 7 drinks per week for women and> 14 drinks per week for men);
or 4) serious mental illness including schizophrenia and bipolar dis-
order (depression was not excluded if participants were well controlled
on treatment). HIV+ participants with a history of treated syphilis and
a persistently positive rapid plasma reagin (RPR) titer of 1:8 or less
were eligible for the study if there was a decrease in RPR of at least
fourfold at six months after treatment and there were no neurological
symptoms at initial syphilis presentation. Institutional Review Board-
approved informed consent was obtained from all participants.
2.2. Sample processing and laboratory protocol
Blood and CSF samples came from the same visit on the same
chronological date. Samples were processed with a standard protocol at
the Emory Infectious Diseases Clinical Research Laboratory.
Speciﬁcally, blood is collected in Becton Dickinson ACD citrated tubes.
Tubes are then centrifuged at 2400 rotations per minute (RPM) for
10min. Plasma supernatant is then removed and re-spun at 2400 RPM
for an additional 10min. The resulting sample is then aliquoted into
cryovials and then stored in a −80 °C freezer. Therefore, plasma sam-
ples are not speciﬁcally platelet free. CSF is collected in sterile poly-
propylene tubes and then centrifuged at 300 relative centrifugal force
for 15min. The resulting sample is then aliquoted into cryovials and
also stored in a −80 °C freezer.
All assays were performed during the same seven day period for
both platforms by the same laboratory personnel. All MBA kits were
from the same lot, and all GNR kits were from the same lot. Samples
were run in duplicate with the MBA platform, while as mentioned
previously, the GNR platform automatically creates a triplicate for each
sample that is loaded. While GNR cartridges are only available through
Protein Simple, MBA kits and plates were purchased through Millipore
Sigma (Burlington, Massachusetts). Assays for both platforms were
performed as per company protocol instructions with no deviations. For
the MBA platform, the standards provided by the company are recon-
stituted with 250 μl of deionized water to give a 10,000 picogram/ml
(pg/ml) concentration. Five subsequent serial dilutions are then made
which represent 20% of each preceding concentration. After application
of wash buﬀer to each well the participant samples, 25 μl of participant
sample as well as standard and control are used for each well and
combined with the pre-mixed beads. There is no dilution of the samples
with the MBA platform. After processing, individual plates are run on
the Luminex Flexmap 3D system. There are two control samples pro-
vided with the MBA kits. The between-plate CV% for control #1 (which
represented lower values) were 4.56 for MCP-1, 20.3 for TNFα, and
85.3 for FKN. The between-plate CV% for control #2 (which re-
presented higher values) were 3.3 for MCP-1, 2.7 for TNFα, and 36.3
for FKN. Please note that the Flexmap 3D system does not adjust results
of plate samples on the basis of the control results.
For the GNR platform, the company protocol was again used with
no deviations. Brieﬂy, the barcode for the cartridge provided by the
company is scanned into the device (which is named “Ella”). One
milliliter of wash buﬀer is then added to each well. Like the MBA
platform, 25 μl of participant sample is needed for each well. In contrast
to the MBA platform, a 1:2 dilution of participant sample is used for
each well. The standards come pre-loaded in the cartridge by the
company. Unlike the MBA system, there are no controls provided for
the GNR platform unless speciﬁcally requested. The cartridge is then
placed into the Ella device and processed automatically with no inter-
ruptions.
Lowest limits of detection as provided by the company for the MBA
assays were: 1.9 picograms (pg)/ milliliter (ml) for MCP-1, 0.7 pg/ml
for TNFα, and 22.7 pg/ml for FKN. Lowest limits of detection as pro-
vided by the company for the GNR assays were: 0.35 pg/ml for MCP-1,
0.278 pg/ml for TNFα, and 18.2 pg/ml for FKN. The coeﬃcient of
variation (CV) % is derived automatically by both individual platforms
with no manual calculations ((Standard deviation/mean)x100).
2.3. Statistical analyses
SAS JMP software version 13 was used for analyses and SAS IML
studio 13 was used for graphics. Normality of variable distribution was
assessed with the Shapiro-Wilk test. Given the skewed distribution of
most variables, comparisons between continuous variables were per-
formed with the Wilcoxon rank sum test. For same-visit and long-
itudinal paired variable comparison, the Wilcoxon signed rank test was
used. For categorical variables, Fisher's exact test was used. For corre-
lations, Spearman's rho test was used. Alpha level for signiﬁcance was
set at< 0.05 and was two tailed.
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3. Results
There were 41 HIV-infected individuals at baseline, with 29 re-
turning for repeat testing 24–48weeks after starting cART. Table 1
shows baseline demographic and disease characteristics. The median
age was 40 years and the majority of participants (75.6%) were African-
American men. Comorbidities were minimal (three participants had
hypertension, two participants had chronic hepatitis B virus (HBV) in-
fection, one participant had chronic hepatitis C virus (HCV) infection,
and one participant had diabetes). Both assays yielded consistently
detectable concentrations at both visits for MCP-1 in both ﬂuids and for
TNFα from plasma. CSF MCP-1 concentrations were consistently higher
at both visits with the MBA assay (both p < .0001), and plasma TNFα
concentrations were also consistently higher at both visits with the
MBA assay (both p < .0001). With the MBA platform, CSF TNFα
concentrations were all detectable (100%) at visit one and detectable
for all but one (97%) at visit two. With the GNR platform, 34 of 41
(82.9%) samples were detectable for CSF TNFα at visit one and 23 of 29
(79.3%) samples were detectable at visit two. Therefore, CSF TNFα was
more likely to be detectable with the MBA platform at the ﬁrst visit
(p= .01) with a trend towards higher detectability at the second visit
(p= .1). All but one sample yielded detectable FKN concentrations for
both ﬂuids at both visits for the GNR platform. For the MBA platform,
plasma FKN was detectable in 37 of 41 visit one samples (90.2%) and
28 of 29 visit two samples (96.6%), meaning that plasma FKN detect-
ability was not signiﬁcantly diﬀerent between platforms. However, CSF
FKN concentrations on the MBA assay were below the limit of detection
in 36 of 41 visit one samples (87.8%) and 24 of 29 visit two samples
(82.8%), meaning that CSF FKN detectability was signiﬁcantly higher
for the GNR assay at both visits (p < .0001).
In Table 2, biomarker coeﬃcient of variation (CV) results and be-
tween-platform correlations are shown for visit 1. For MCP-1, con-
centrations correlated signiﬁcantly between platforms for both ﬂuids
(see Fig. 1 for plasma correlation with 80% density ellipse, with units
being picograms/ml for both axes), and the coeﬃcient of variation (CV)
was signiﬁcantly lower with the MBA platform for the measurement of
CSF MCP-1. For TNFα, only plasma concentrations correlated sig-
niﬁcantly between the two platforms, and the CV was signiﬁcantly
lower with the GNR platform with this ﬂuid. Neither plasma nor CSF
FKN concentrations correlated signiﬁcantly between the two platforms,
and CV was signiﬁcantly lower with the GNR platform for the mea-
surement of both plasma and CSF FKN. Neither platform yielded a
signiﬁcant correlation between plasma MCP-1 and log10 plasma HIV
RNA or a signiﬁcant correlation between CSF MCP-1 and log10 CSF HIV
RNA. The only signiﬁcant TNF-HIV correlation was between CSF TNFα
and log10 CSF HIV RNA using the MBA platform (rho=0.71,
p < .0001, see Fig. 2). The only signiﬁcant FKN-HIV correlation was
between plasma FKN and log10 plasma HIV RNA using the GNR plat-
form (rho=0.38, p= .015, see Fig. 3).
At visit 2 (Table 3), 22 of 29 participants (76%) had achieved both
plasma and CSF HIV RNA < 400 copies/ml. Just as in visit 1, both
plasma and CSF MCP-1 concentrations as well as plasma TNFα con-
centrations correlated signiﬁcantly between the two platforms (all
p < .005). Again, however, CSF TNFα concentrations as well as both
plasma and CSF FKN concentrations did not correlate signiﬁcantly be-
tween the two platforms. FKN CV was again signiﬁcantly lower with the
GNR platform for both plasma and CSF. Between visits, both platforms
detected statistically signiﬁcant decreases in plasma and CSF MCP-1 as
well as plasma TNFα after initiation of cART (see Table 4). While the
MBA platform detected a statistically signiﬁcant decrease in CSF TNFα,
the GNR platform did not, even when excluding participants who had
an undetectable concentration at the ﬁrst visit. In contrast, only the
GNR platform detected a statistically signiﬁcant decrease in plasma
FKN.
4. Discussion
Until a cure is eventually found, HIV will very likely continue to be
a pro-inﬂammatory disease that is associated with adverse outcomes.
These include adverse CNS eﬀects such as neuronal damage and HIV-
associated neurocognitive disorder. Therefore, high sensitivity methods
that are scalable and precise will be needed to measure inﬂammatory
biomarkers, including from the CNS. In this study, we evaluated a re-
latively new platform based on glass nanoreactor (GNR) technology in
relationship to the established multiplex bead array (MBA) as a means
to quantitate HIV-associated biomarkers from both CSF and plasma.
The GNR platform is a novel technology based on microﬂuidics. To our
knowledge, this is the ﬁrst study evaluating the GNR platform for the
quantitation of CSF biomarkers during HIV infection.
We found that MCP-1 concentrations from both plasma and CSF
consistently correlated between the two platforms, as did TNFα con-
centrations from plasma. However, CSF TNFα concentrations (which
only correlated with CSF HIV RNA level using the MBA platform and for
which signiﬁcant change could only be detected with the MBA plat-
form) did not correlate between platforms. While TNFα concentrations
from blood are known to decrease after initiation of cART (McComsey
et al., 2014), TNFα remains elevated despite long term HIV suppression
(Wada et al., 2015). TNFα has long been recognized as a neurotoxic
cytokine with damaging eﬀects on both neurons and oligodendrocytes
Table 1
Demographic and Disease characteristics of participants.
Variable (N=41) Median (IQR) or Number (%)
Age in years 40 (33–47)
Male Sex 33 (80.5%)
Race
African American 36 (87.8%)
White 5 (12.2%)
Blood Tests
CD4+ Current (per μl) 94 (30−302)
Creatinine (mg/dl) 0.9 (0.8–1.1)
HIV RNA (log10 copies/ml) 4.61 (4.0–5.27)
CSF Tests
WBC (per μl) 1 (0–6)
RBC (per μl) 0 (0–1.5)
HIV RNA (log10 copies/ml) 3.1 (2.1–3.77)
IQR= interquartile range; CD= cluster of diﬀerentiation, μl=microliter;
mg=milligrams; dl= deciliters; ml=milliliters; HIV=human im-
munodeﬁciency virus; RNA= ribonucleic acid; CSF= cerebrospinal ﬂuid;
WBC=white blood cell count; RBC= red blood cell count.
Table 2
Visit 1 biomarker comparisons.
Analyte
(n= 41)
Fluid Platform CV in % Median
(IQR)
Correlation between
platforms (p value)
MCP-1 Plasma MBA 2.8 (1.4–4.8) 0.69 (< 0.0001)
GNR 3.2 (1.7–3.6)
MCP-1 CSF MBA 2.4 (0.9–4.1) 0.74 (< 0.0001)
GNR 4.5 (2.8–6.3)*
TNFα Plasma MBA 5.5 (2.3–8.9) 0.5 (0.001)
GNR 2.2 (1.3–2.6)*
TNFα CSF MBA 4.6 (3.0–10.2) −0.04 (0.82)
GNR 2.3 (1.0–11.2)
Fractalkine Plasma MBA 8.3 (4.1–15.2) 0.1 (0.6)
GNR 1.8 (1.2–2.3)*
Fractalkine CSF MBA 17.4 (8.5–29.9) – –
GNR 5.5 (3.3–9.1)*
CV= coeﬃcient of variation; IQR= interquartile range; MBA=multiplex
bead array platform; GNR=glass nanoreactor platform; CSF= cerebrospinal
ﬂuid; * denotes p < .005 for CV diﬀerence between platforms; Spearman's rho
used for correlation. – denotes that the majority of CSF fractalkine values were
undetectable with MBA platform.
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(Selmaj and Raine, 1988). It is elevated in the CSF of individuals with
diseases such as sub-arachnoid hemorrhage and progressive multiple
sclerosis (Rossi et al., 2014; Wu et al., 2016). In early pre-cART re-
search, CSF TNFα concentrations correlated signiﬁcantly with CSF HIV
RNA (Lafeuillade et al., 1996). In our study, this ﬁnding was only re-
plicated with the MBA platform. Based on our ﬁndings, the MBA plat-
form may be preferable for measuring this cytokine from CSF.
In contrast, we found that the GNR platform was signiﬁcantly more
sensitive than the MBA platform for the measurement of FKN, with
higher intra-assay precision and capability to detect signiﬁcant change
over time. Plasma FKN only correlated with plasma HIV using the GNR
platform. FKN is a potent chemokine that attracts and activates leu-
kocytes such as brain macrophages and microglia, and has been shown
to be expressed at higher levels in the CNS compared to the periphery
(Bazan et al., 1997; Cotter et al., 2002). In addition to an association
with HIV infection, CSF FKN concentrations have been found to be
elevated in other diseases such as neuropsychiatric systemic lupus er-
ythematosus (SLE) (Yajima et al., 2005). While some studies show that
FKN has neuroprotective properties, others point to neurotoxic prop-
erties based on upregulation of inﬂammation (Lauro et al., 2015).
Therefore, further study is needed to better understand the eﬀects of
this chemokine during HIV and other diseases. Based on our ﬁndings,
the GNR platform may be preferable for measuring FKN from both
plasma and CSF.
We acknowledge the limitations of this small study. There are many
other markers that have been found to be altered during HIV, including
C-reactive protein (CRP), IL-6, soluble CD14 and soluble CD163 (Hunt
et al., 2016). Examination of these markers would have strengthened
the study, but these examinations would have been beyond the scope of
this research project, which had speciﬁc aims and funding. Future
studies that compare biomarker platforms should consider including
these additional markers. While three markers correlated signiﬁcantly
between the two platforms, the values were far from being exactly the
same, with the highest Spearman's correlation coeﬃcient being 0.74.
All of the samples were run over a single seven day period with the
same laboratory personnel. The kits that were used for each platform
Fig. 1. Correlation graph with 80% density ellipse between plasma monocyte chemoattractant protein-1 (MCP-1) concentrations obtained by multiplex bead array
assay (Luminex platform, on x-axis) and plasma MCP-1 concentrations obtained by glass nanoreactor assay (Protein Simple platform, on y-axis). Units for both axes
are picograms/milliliter. Results are from HIV-infected participants oﬀ antiretroviral treatment.
Fig. 2. Correlation graph with 80% density ellipse between cerebrospinal ﬂuid (CSF) tumor necrosis factor alpha concentrations in picograms/milliliter obtained by
multiplex bead array assay (Luminex platform, on x-axis) and CSF HIV RNA concentrations (copies/milliliter, log10 transformed) obtained by polymerase chain
reaction (Abbott laboratories m2000 Real Time HIV-1 assay system, on y-axis). Results are from HIV-infected participants oﬀ antiretroviral treatment.
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were from the same lot. The coeﬃcient of variation (CV) % was derived
automatically by both platforms with no manual calculations ((Stan-
dard deviation/mean) x 100). However, we did not examine inter-assay
precision as would be determined, for example, by measurement of the
same samples on diﬀerent days. Therefore our results do not take into
account diﬀerences based on the day the assay was performed. Also, we
did not examine accuracy as would be determined by quantitating
markers from samples with previously determined concentrations.
The inclusion of a third, more traditional method such as ELISA
would have strengthened the study by providing a standard to which
the two newer platforms could be compared. However, this would have
been beyond the scope of the project, which had speciﬁc grant funded
aims. Pipetting and other factors that inﬂuence the preparation of plates
may have inﬂuenced CV% diﬀerence between the two platforms.
Speciﬁcally, the MBA platform requires two separate wells for the du-
plicate values that are produced. In contrast, the GNR platform does not
require separate wells for the triplicate values that are produced.
Rather, these triplicate values are produced automatically as the sample
travels through the three glass nanoreactors that are associated with
each analyte. Therefore, it is possible that having to create two separate
wells may inﬂuence the CV% that are produced with the MBA platform.
There was a particularly strong diﬀerence in CV% values for FKN be-
tween the two platforms, and this diﬀerence in replicate production
between platforms may have played a role.
The sample size of the study was relatively limited, meaning that
small diﬀerences between the platforms may have been missed. Due to
small sample size, we did not examine biomarker associations with
neuropsychological performance. The persistence of neurocognitive
impairment continues to be problematic in the cART era, and a better
understanding of how inﬂammation inﬂuences impairment is needed.
We and other groups are working to address this question in larger
biomarker studies with more power to detect signiﬁcant eﬀects. Other
than diﬀerences in performance, a number of other factors (including
time and cost) play a role when investigators decide how to measure
soluble biomarkers. As mentioned, the GNR platform cartridges come
with pre-established factory calibrated standard curves. For this and
other reasons related to the setup of the assay, the GNR plates are more
automated and require< 50% of the time to run than the MBA plates in
our experience. These characteristics could reduce institution-to-in-
stitution, lab-to-lab and user-to-user variability. However, the GNR kits
were > 50% more expensive than the MBA kits in our experience. Cost
is often a major consideration, particularly when performing large
Fig. 3. Correlation graph with 80% density ellipse between plasma fractalkine concentrations (in picograms/milliliter) obtained by glass nanoreactor assay (Protein
Simple platform, on x-axis) and plasma HIV RNA concentrations (copies/milliliter, log10 transformed) obtained by polymerase chain reaction (Abbott laboratories
m2000 Real Time HIV-1 assay system, on y-axis). Results are from HIV-infected participants oﬀ antiretroviral treatment.
Table 3
Visit 2 biomarker comparisons.
Analyte
(n= 29)
Fluid Platform CV in % Median
(IQR)
Correlation between
platforms (p value)
MCP-1 Plasma MBA 3.6 (1.4–6.8) 0.74 (< 0.0001)
GNR 2.5 (1.0–3.2)
MCP-1 CSF MBA 2.1 (1.3–3.3) 0.64 (0.0002)
GNR 3.3 (2.1–4.8)
TNFα Plasma MBA 3.5 (1.2–8.2) 0.53 (0.004)
GNR 2.3 (0.9–4.3)
TNFα CSF MBA 8.5 (5.4–14.9) −0.25 (0.26)
GNR 1.1 (0.3–8.3)
Fractalkine Plasma MBA 15.4 (7.2–23.2) −0.01 (0.95)
GNR 1.8 (1.1–2.7)*
Fractalkine CSF MBA 24.4 (10.2–36.1) – –
GNR 6.5 (3.8–10.3)*
CV= coeﬃcient of variation; IQR= interquartile range; MBA=multiplex
bead array platform; GNR=glass nanoreactor platform; CSF= cerebrospinal
ﬂuid; * denotes p < .005 for CV diﬀerence between platforms; Spearman's rho
used for correlation. – denotes that the majority of CSF fractalkine values were
undetectable with MBA platform.
Table 4
Biomarker change between visits.
Analyte
(n= 29)
Fluid Platform Median change between visits
(IQR)
P value
MCP-1 Plasma MBA −56.0 (−190.8–+21.5) 0.004
GNR −93.8 (−219.2 to −31.7) 0.0001
MCP-1 CSF MBA −471.0 (−1026.0 to
−120.5)
<0.0001
GNR −48.6 (−142.7–+8.3) 0.009
TNFα Plasma MBA −6.4 (−13.5–+0.6) 0.001
GNR −5.5 (−8.0 to −2.0) <0.0001
TNFα CSF MBA −1.8 (−3.0 to −0.5) <0.0001
GNR 0.0 (−0.7–+0.9) 0.95
Fractalkine Plasma MBA +9.0 (−35.7–+118.6) 0.27
GNR −275.4 (−924.8 to −88.8) 0.001
Fractalkine CSF MBA – – –
GNR +6.5 (−38.4–+63.8) 0.48
MBA=multiplex bead array platform; GNR=glass nanoreactor platform;
CSF= cerebrospinal ﬂuid;−- denotes that change could not be calculated due
to majority of values being undetectable.
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numbers of samples. Lastly, multiple other companies oﬀer MBA kits,
and the scope of this project was not broad enough to compare kits from
multiple diﬀerent vendors on the MBA platform.
5. Conclusions
Fractalkine results did not correlate between MBA and GNR plat-
forms for plasma or CSF, nor did TNFα results from CSF. The GNR
platform performance appeared to be superior for the quantitation of
FKN, while the MBA platform performance appeared to be superior for
CSF TNFα quantitation. Overall, more research is needed on the simi-
larities and diﬀerences of platforms for the measurement of im-
munologic markers in HIV and other disease states.
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